Opko Health stock gains on FDA announcement
Opko Health shares traded up 1.5 percent on Tuesday afternoon after the FDA decided to initiate a review of the company’s Rayaldee drug candidate.
The Miami-based biotech and pharmaceutical company (NYSE: OPK), headed by billionaire Chairman and CEO Dr. Phillip Frost, is seeking approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D (CKD) deficiency. Opko submitted an application for the drug based…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Brian Bandell Source Type: news
More News: Biotechnology | Chronic Kidney Disease | Health | Health Management | Hyperparathyroidism | Urology & Nephrology | Vitamin D Deficiency | Vitamins